SHARRON FORSBERG: Open Payments
NPI 1144672239 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$735 in 12 payments from 9 companies in 2025. Trend: 2023 $909 · 2024 $741 · 2025 $735
Food & beverage: $735
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 3 | $254 |
| Janssen Biotech, Inc. | 2 | $150 |
| GENZYME CORPORATION | 1 | $144 |
| Geron Corporation | 1 | $67 |
| Genentech USA, Inc. | 1 | $33 |
| ABBVIE INC. | 1 | $31 |
| PFIZER INC. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Syndax Pharmaceuticals, Inc. | 1 | $16 |
Products named: Lenvima, SARCLISA, RYBREVANT, RYTELO, Tecentriq, EPKINLY, IBRANCE, Enhertu.
Industry payments across NE — which companies pay providers there.
